Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 18 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 Planned initiation date changed from 31 Jul 2017 to 31 Oct 2017.
- 27 Jun 2017 New trial record